Skip to main content
SpringerLink
Log in

CD133 expression: a potential prognostic marker for non-small cell lung cancers

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

CD133 is a membrane glycoprotein containing five transmembrane loops. Previous reports suggest that a CD133-positive subpopulation of multipotent cells with extensive proliferative and self-renewal characteristics has biological features of a cancer stem cell. In addition, the presence of CD133-positive cells was associated with a significantly poorer prognosis for some solid tumors, compared to those with CD133-negative cells. However, the clinicopathological significance of CD133 in non-small cell lung cancer (NSCLC) remains controversial.

Methods

We conducted immunohistochemical assessment of 161 NSCLCs surgically resected at Hokkaido University Hospital between 1982 and 1994 to evaluate correlations between CD133 expression and various clinicopathological features.

Results

CD133 expression was significantly correlated with pathological stages (pStages) II, III, and IV for the various NSCLC types analyzed and was an independent factor for unfavorable prognosis in this population (hazard ratio = 3.157, P = 0.015).

Conclusion

CD133 expression was correlated with pStage and was predictive of unfavorable prognosis in patients with pStages II, III, and IV NSCLC. These results suggest the possibility of using CD133 as a novel prognostic marker in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Miraglia S, Godfrey W, Yin AH et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021

    PubMed  CAS  Google Scholar 

  3. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature (Lond) 445:111–115

    Article  CAS  Google Scholar 

  4. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature (Lond) 432:396–401

    Article  CAS  Google Scholar 

  5. Horst D, Kriegl L, Engel J et al (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285–1289

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Zeppernick F, Ahmadi R, Campos B et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123–129

    Article  PubMed  CAS  Google Scholar 

  7. Zhao P, Li Y, Lu Y (2010) Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 10:218

    Article  PubMed Central  PubMed  Google Scholar 

  8. Song W, Li H, Tao K et al (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62:1212–1218

    Article  PubMed  CAS  Google Scholar 

  9. Salnikov AV, Kusumawidjaja G, Rausch V et al (2009) Cancer stem cell marker expression in hepatocellular carcinoma and liver metastasis is not sufficient as single prognostic parameter. Cancer Lett 275:185–193

    Article  PubMed  CAS  Google Scholar 

  10. Donnenberg VS, Landreneau RJ, Donnenberg AD (2007) Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release 122:385–391

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281–16286

    Article  PubMed Central  PubMed  Google Scholar 

  12. Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4:32–42

    PubMed Central  PubMed  Google Scholar 

  13. Zhang HZ, Wei YP, Wang M et al (2007) Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27:696–699

    PubMed  CAS  Google Scholar 

  14. Salnikov AV, Gladkich J, Moldenhauer G et al (2010) CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126:950–958

    PubMed  CAS  Google Scholar 

  15. Li F, Zeng H, Ying K (2010) The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28:1458–1462

    Article  PubMed  CAS  Google Scholar 

  16. Beahrs O, Henson D, Hutter R et al (1992) AJCC manual for staging of cancer, lung. Lippincott, Philadelphia

    Google Scholar 

  17. Hermansen SK, Christensen KG, Jensen SS et al (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59:391–407

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Sasaki A, Kamiyama T, Yokoo H et al (2010) Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 24:537–546

    Article  PubMed  CAS  Google Scholar 

  19. Sagrinati C, Netti GS, Mazzinghi B et al (2006) Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol 17:2443–2456

    Article  PubMed  CAS  Google Scholar 

  20. Hilbe W, Dirnhofer S, Oberwasserlechner F et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965–969

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253–1261

    Article  PubMed  CAS  Google Scholar 

  22. Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature (Lond) 414:105–111

    Article  CAS  Google Scholar 

  23. Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951

    Article  PubMed  CAS  Google Scholar 

  24. Suetsugu A, Nagaki M, Aoki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820–824

    Article  PubMed  CAS  Google Scholar 

  25. Eramo A, Lotti F, Sette G et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514

    Article  PubMed  CAS  Google Scholar 

  26. Horst D, Scheel SK, Liebmann S et al (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219:427–434

    Article  PubMed  CAS  Google Scholar 

  27. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768

    Article  PubMed  CAS  Google Scholar 

  28. Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120

    PubMed Central  PubMed  CAS  Google Scholar 

  29. Janikova M, Skarda J, Dziechciarkova M et al (2010) Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:321–326

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Namie Sawada (Department of Medical Oncology, Hokkaido University Graduate School of Medicine) for special support and experimental assistance.

Conflict of interest

All authors report that they have no financial conflicts of interest.

Author information

Authors and Affiliations

  1. First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan

    Hidenori Mizugaki, Jun Sakakibara-Konishi, Junko Kikuchi, Eiki Kikuchi, Satoshi Oizumi & Masaharu Nishimura

  2. Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

    Jun Moriya, Kanako C. Hatanaka & Yoshihiro Matsuno

  3. Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Ichiro Kinoshita & Hirotoshi Dosaka-Akita

Authors
  1. Hidenori Mizugaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Sakakibara-Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junko Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Moriya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kanako C. Hatanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiki Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiro Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Oizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirotoshi Dosaka-Akita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshihiro Matsuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masaharu Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Sakakibara-Konishi.

About this article

Cite this article

Mizugaki, H., Sakakibara-Konishi, J., Kikuchi, J. et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 19, 254–259 (2014). https://doi.org/10.1007/s10147-013-0541-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0541-x

Keywords

Search

Navigation